University of Maryland, Baltimore-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2021

  1. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

    Blood Cancer Journal, Vol. 11, Núm. 12

2020

  1. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    The Lancet Oncology, Vol. 21, Núm. 2, pp. 207-221

  2. Id1 and pd-1 combined blockade impairs tumor growth and survival of KRAS-mutant lung cancer by stimulating PD-l1 expression and tumor infiltrating CD8+ T cells

    Cancers, Vol. 12, Núm. 11, pp. 1-22

2017

  1. Second primary malignancies in multiple myeloma: An overview and IMWG consensus

    Annals of Oncology, Vol. 28, Núm. 2, pp. 228-245

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  2. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease

    American Journal of Human Genetics, Vol. 98, Núm. 6, pp. 1193-1207

2013

  1. Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    Leukemia, Vol. 27, Núm. 4, pp. 780-791

2004

  1. Screening and interventions for obesity in adults [4] (multiple letters)

    Annals of Internal Medicine